Literature DB >> 18445006

Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells.

Nicolas Montcuquet1, Patricia Mercier-Letondal, Sylvain Perruche, Anne Duperrier, Mélanie Couturier, Abdelghani Bouchekioua, Mark Bonyhadi, Christophe Ferrand, Pierre Tiberghien, Eric Robinet.   

Abstract

CD3- and CD28-activated T cells expanded for 12 days ex vivo to produce suicide gene-modified T cells are hyporesponsive to alloantigens. To investigate whether this impaired alloreactivity is a result of preferential expansion of regulatory T (Treg) cells, we compared peripheral blood mononuclear cells (PBMC) activated with CD3 and CD28 antibodies co-immobilized on beads and expanded for 12 days with interleukin (IL)-2 (Co(CD3/CD28) cells) to the respective unactivated PBMC in terms of proliferation, cytokine production, and expression of Treg markers [cytotoxic T-lymphocyte antigen 4 (CTLA4), glucocorticoid-induced tumour necrosis factor receptor (GITR) and forkhead box P3 (FoxP3)] after allostimulation. Alloreactive cells were identified by carboxyfluoresceine succinimidyl ester staining dilution. Alloreactive cells in Co(CD3/CD28) cells had a lower proliferative response and a lower potential for IL-2 and interferon-gamma secretion than did those in PBMC, demonstrating a functional impairment of alloreactive cells during ex vivo expansion. Expression of Treg markers transiently increased during ex vivo expansion and was unaffected by depletion of CD25(+) cells (containing Treg cells) before ex vivo PBMC expansion. Such prior CD25(+) depletion did not restore the alloreactivity of Co(CD3/CD28) cells. After allostimulation, expression of Treg markers was restricted to proliferative (alloreactive) cells among PBMC or Co(CD3/CD28) cells. Lastly, CD4(+) CD25(+) cells purified from Co(CD3/CD28) cells lacked suppressive activity when used as a third party, in contrast to CD4(+) CD25(+) cells purified from PBMC. In conclusion, the impaired alloreactivity of T cells expanded ex vivo is not a result of preferential Treg cell expansion and/or enhanced suppressive Treg activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18445006      PMCID: PMC2669136          DOI: 10.1111/j.1365-2567.2008.02843.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  Influence of ex vivo expansion and retrovirus-mediated gene transfer on primary T lymphocyte phenotype and functions.

Authors:  Delphine Sauce; Nicolas Tonnelier; Anne Duperrier; Bruno Petracca; Marcelo de Carvalho Bittencourt; Mounir Saadi; Philippe Saas; Christophe Ferrand; Patrick Herve; Pierre Tiberghien; Eric Robinet
Journal:  J Hematother Stem Cell Res       Date:  2002-12

2.  Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire.

Authors:  C Ferrand; E Robinet; E Contassot; J M Certoux; A Lim; P Hervé; P Tiberghien
Journal:  Hum Gene Ther       Date:  2000-05-20       Impact factor: 5.695

3.  Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells.

Authors:  Delphine Sauce; Nathalie Rufer; Patricia Mercier; Marie Bodinier; Jean-Paul Rémy-Martin; Anne Duperrier; Christophe Ferrand; Patrick Hervé; Pedro Romero; François Lang; Pierre Tiberghien; Eric Robinet
Journal:  Blood       Date:  2003-05-01       Impact factor: 22.113

4.  Retrovirus-mediated gene transfer in human primary T lymphocytes induces an activation- and transduction/selection-dependent TCR-B variable chain repertoire skewing of gene-modified cells.

Authors:  Sylvie Coito; Delphine Sauce; Anne Duperrier; Jean-Marie Certoux; Mark Bonyhadi; Alexis Collette; Klaus Kuehlcke; Patrick Hervé; Pierre Tiberghien; Eric Robinet; Christophe Ferrand
Journal:  Stem Cells Dev       Date:  2004-02       Impact factor: 3.272

5.  In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures.

Authors:  Wayne R Godfrey; Ying G Ge; Darrin J Spoden; Bruce L Levine; Carl H June; Bruce R Blazar; Stephen B Porter
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

6.  Reduced graft-versus-host disease-inducing capacity of T cells after activation, culturing, and magnetic cell sorting selection in an allogeneic bone marrow transplantation model in rats.

Authors:  Mo Weijtens; Anke van Spronsen; Anton Hagenbeek; Eric Braakman; Anton Martens
Journal:  Hum Gene Ther       Date:  2002-01-20       Impact factor: 5.695

7.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft.

Authors:  P Tiberghien; C Ferrand; B Lioure; N Milpied; R Angonin; E Deconinck; J M Certoux; E Robinet; P Saas; B Petracca; C Juttner; C W Reynolds; D L Longo; P Hervé; J Y Cahn
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

8.  Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms.

Authors:  Delphine Sauce; Marie Bodinier; Marina Garin; Bruno Petracca; Nicolas Tonnelier; Anne Duperrier; Junia V Melo; Jane F Apperley; Christophe Ferrand; Patrick Hervé; François Lang; Pierre Tiberghien; Eric Robinet
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

9.  Functional and phenotypic variations in human T cells subjected to retroviral-mediated gene transfer.

Authors:  M L Lamana; J A Bueren; J L Vicario; A Balas
Journal:  Gene Ther       Date:  2004-03       Impact factor: 5.250

10.  Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy.

Authors:  R F Duarte; F E Chen; M W Lowdell; M N Potter; M L Lamana; H G Prentice; J A Madrigal
Journal:  Gene Ther       Date:  2002-10       Impact factor: 5.250

View more
  1 in total

1.  In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells.

Authors:  Céline Leboeuf; Laurent Mailly; Tao Wu; Gaetan Bour; Sarah Durand; Nicolas Brignon; Christophe Ferrand; Christophe Borg; Pierre Tiberghien; Robert Thimme; Patrick Pessaux; Jacques Marescaux; Thomas F Baumert; Eric Robinet
Journal:  Mol Ther       Date:  2013-12-06       Impact factor: 11.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.